Rare Anaemias, Sickle-Cell Disease and COVID-19

Main Article Content

Joan-Lluis Vives Corrons
Vincenzo De Sanctis




For rare haematological diseases (RHD), the first question to be answered is if patients with be- nign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor.


Download data is not yet available.
Abstract 1035 | PDF Downloads 750


1.World Health Organisation. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

2. European Commission. Health and Food Safety Directorate General. “COVID.19 Clinical Management Support System”. e-News. 27/03/2020. https://www.vml.org/enews-march-27-2020/.

3. COVID-19 and Rare Diseases. Orphanews 27 of March 2020. https://www.drroyspencer.com/2020/03/covid-19-deaths-in-europe-excess-mortality-is-down/.

4. COVID-19 and Rare Hematological Diseases. EuroBloodNet https://eurobloodnet.eu/covid-19/.

5.Thalassemia International Federation .The COVID–19 pandemic and haemoglobin disorders. A contribution of Thalassaemia International Federation to its global patients’ community.

6. . Haemoglobinopathy Co-ordinating Centres. https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f05/.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>